Primary Job Title Scientific Advisory Board Primary Organization 
Anavex
Gender Male
A member of the Scientific Advisory Board, Dr. Gold has over 20 years of experience in the clinical development of Alzheimer’s and other central nervous system (CNS) drugs, and currently serves as Vice President of the CNS practice at UCB, Inc., a global biopharmaceutical company.
His background also includes leadership roles with
GlaxoSmithKline (GSK), Johnson & Johnson (J&J) and Bristol-Myers Squibb (BMS).
At GSK, Dr. Gold was responsible for the late-stage CNS and pain portfolio.
He also led several clinical Phase II and Phase III Alzheimer’s disease-related project teams.
At J&J, Dr. Gold served as the Compound Development Team Leader for Galantamine, an Alzheimer’s drug, culminating in FDA approval of Galantamine CR (Razadyne® ER).
Prior to joining UCB, Dr. Gold served as the Chief Medical Officer of Allon Therapeutics, where he led a large pan-US and European clinical study for a neurodegenerative disease.
Before joining the pharmaceutical industry, Dr. Gold was an Assistant Professor at the University of South Florida (USF) College of Medicine Department of Neurology and Director of the USF Memory Disorders Clinic.
During this time, he was the Principal Investigator for several clinical trials for Alzheimer’s disease.
He has also authored multiple publications related to Alzheimer’s and dementia.
Dr. Gold also holds an academic appointment as an adjunct assistant professor in the Department of Medicine at the University of North Carolina at Chapel Hill.
